PROCEED + DETECT Year 9 supplement patient care costs
PROCEED + DETECT Year 9 supplement patient care costs
批准号:
10887986
负责人:
Kenneth Cusi
金额:
$13.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-09-28 至 2025-06-30
关键词:
AcuteAddressAdultAncillary StudyBiologicalBiological MarkersBiological Specimen BanksBloodCancer Research ProjectChildChildhoodClinicalClinical ManagementClinical ResearchClinical TrialsCollaborationsCollectionComplexDiabetes MellitusDiagnosisDiseaseDuodenumEarly DiagnosisEducational workshopExocrine pancreatic insufficiencyFecesFosteringFunctional disorderFutureGoalsJuiceMalignant neoplasm of pancreasMethodsNatural HistoryNon-Insulin-Dependent Diabetes MellitusPancreasPancreatic DiseasesPancreatitisPathogenesisPathogenicityPatient CarePatientsPediatric cohortPhenotypePreventionProtocols documentationRecurrenceRelapseResearchResourcesSalivaSamplingStrategic PlanningStructureTherapeuticTimeTissuesTranslational ResearchUnited States National Institutes of HealthUrineWorkacute pancreatitisbiomarker validationcare costschronic painchronic pancreatitiscohortimprovedprospectiveradiological imagingrecruitrisk stratificationspecific biomarkersworking group
中文摘要
摘要/摘要
慢性胰腺炎、糖尿病和胰腺癌研究联盟
(CPDPC) 的成立是 NIH 主办的多个研讨会的结果,重点关注
确定改善胰腺疾病患者护理的重要研究目标。的
CPDPC 的目标是调查临床上重要的相互关系
胰腺炎、糖尿病和胰腺癌,重点是更好地了解机制,
病理生理学和自然史,改善早期诊断,发现特异性
生物标志物,并最终作为探索性和后续更大规模的平台
临床试验。 CPDPC 通过设立多个机构来开展这些工作
通过形成几个工作组来协调和规划前瞻性患者队列
组。这些工作组 (WG) 包括 CP 成人工作组、CP 儿科工作组、DM PDAC
WG 和 Type3C DM WG。由 CP 成人工作组组织的 PROCEED 队列将
最终包括 1600 名成年受试者,重点关注患有急性、急性复发、
和慢性胰腺炎。由 CP 儿科工作组组织的 INSPIRRE 2 队列将
包括 860 名患有急性复发性和慢性胰腺炎的儿童。检测队列,
由 Type3C DM WG 组织,正在招募患有典型 2 型糖尿病的受试者作为
以及因胰腺癌或慢性胰腺炎而患有糖尿病的患者,以确定
这些类型的糖尿病之间的机制差异,并利用该信息
生物标志物和治疗益处。每个队列将代表大量深度样本
表型和特征化的受试者,具有全面注释的生物样本(生物
样本、射线照相)收集,并随着时间的推移对其进行跟踪。这些群体,当完全
招募和跟进,提供独特而强大的资源来解决许多问题
未解答的临床问题并解决 CPDPC 章程的目标。 CPDPC 是
组织起来允许大量辅助研究与主要队列并行进行
招募,这些辅助研究现在数量超过 50 项。这些辅助研究
帮助为 CPDPC 的工作提供信息,并建立了一套方法和协议
指导联盟,并为未来的临床提供明确的方法和定义
对这些疾病的研究。 CPDPC 的结构提供了无与伦比的机会
进行内部和外部合作,以促进临床研究并开发更有效的
复杂胰腺疾病的预测、预防和治疗。
英文摘要
Summary/Abstract
The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
(CPDPC) was formed as a consequence of several NIH-sponsored workshops focused on
defining important research goals for improving care of patients with pancreatic diseases. The
goals of the CPDPC have been to investigate the clinically important inter-relationships between
pancreatitis, diabetes, and pancreatic cancer, focused on better understanding mechanisms,
pathophysiology, and natural history, on improving early diagnosis, discovering specific
biomarkers, and ultimately serving as a platform for exploratory and subsequent larger-scale
clinical trials. The CPDPC undertook these efforts through the establishment of several
prospective patient cohorts, coordinated and planned through the formation of several working
groups. These working groups (WGs) include the CP Adult WG, CP Pediatric WG, DM PDAC
WG, and the Type3C DM WG. The PROCEED cohort, organized by the CP Adult WG, will
ultimately include 1600 adult subjects, and is focused on patients with acute, acute relapsing,
and chronic pancreatitis. The INSPIRRE 2 cohort, organized by the CP Pediatric WG, will be
comprised of 860 children with acute relapsing and chronic pancreatitis. The DETECT cohort,
organized by the Type3C DM WG, is recruiting subjects with typical Type 2 diabetes mellitus as
well as patients with diabetes due to pancreatic cancer or chronic pancreatitis, to determine
mechanistic differences between these types of diabetes and leverage that information for
biomarker and therapeutic benefit. Each cohort will represent a large sample of deeply
phenotyped and characterized subjects, with comprehensive annotated biospecimen (biologic
samples, radiographic) collection, who are being followed over time. These cohorts, when fully
recruited and followed-up, provide a unique and powerful resource to address many
unanswered clinical questions and to address the goals of the CPDPC charter. The CPDPC is
organized to allow numerous ancillary studies to proceed in parallel to the main cohort
recruitment, and these ancillary studies now number more than 50. These ancillary studies
have helped inform the work of the CPDPC, and established a set of methods and protocols to
guide the consortium, as well as provide defined methods and definitions for future clinical
research in these diseases. The structure of the CPDPC provides an unparalleled opportunity
for internal and external collaboration to foster clinical studies and develop more effective
prediction, prevention, and treatment of complex pancreatic diseases.
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Biliary intervention rates during neoadjuvant therapy for adenocarcinoma of the pancreatic head.
胰头腺癌新辅助治疗期间的胆道干预率。
DOI:
10.1016/j.hpb.2020.11.1147
发表时间:
2021
期刊:
HPB : the official journal of the International Hepato Pancreato Biliary Association
影响因子:
--
作者:
[Kirkpatrick,Stacey, Gillies,Gwendolyn, Underwood,Patrick, Cioffi,Jessica, Trevino,JoseG, Hughes,StevenJ]
通讯作者:
Hughes,StevenJ
DOI:
10.1186/s40168-022-01262-7
发表时间:
2022-06-15
期刊:
MICROBIOME
影响因子:
15.5
作者:
[Herremans, Kelly M., Riner, Andrea N., Cameron, Miles E., McKinley, Kelley L., Triplett, Eric W., Hughes, Steven J., Trevino, Jose G.]
通讯作者:
Trevino, Jose G.
DOI:
10.1016/j.cytogfr.2020.01.001
发表时间:
2020-03
期刊:
Cytokine & growth factor reviews
影响因子:
13
作者:
[Han S, Underwood P, Hughes SJ]
通讯作者:
Hughes SJ
DOI:
10.1016/j.actbio.2017.11.037
发表时间:
2018-03
期刊:
Acta biomaterialia
影响因子:
9.7
作者:
[Rubiano A, Delitto D, Han S, Gerber M, Galitz C, Trevino J, Thomas RM, Hughes SJ, Simmons CS]
通讯作者:
Simmons CS
DOI:
10.12688/f1000research.20779.1
发表时间:
2019-01-01
期刊:
F1000Research
影响因子:
--
作者:
[Perbtani, Yaseen, Forsmark, Chris E]
通讯作者:
Forsmark, Chris E
共 15 条
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
-
批准号:9917166
-
项目类别:
-
资助金额:$63.15万
-
财政年份:2020
-
负责人:Kenneth Cusi
-
依托单位:
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
-
批准号:10398978
-
项目类别:
-
资助金额:$55.5万
-
财政年份:2020
-
负责人:Kenneth Cusi
-
依托单位:
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
-
批准号:10160896
-
项目类别:
-
资助金额:$59.57万
-
财政年份:2020
-
负责人:Kenneth Cusi
-
依托单位:
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
-
批准号:10613936
-
项目类别:
-
资助金额:$53.86万
-
财政年份:2020
-
负责人:Kenneth Cusi
-
依托单位:
Administrative Supplement (NoD)
-
批准号:9986305
-
项目类别:
-
资助金额:$12.78万
-
财政年份:2015
-
负责人:Kenneth Cusi
-
依托单位:
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
-
批准号:10657642
-
项目类别:
-
资助金额:$45.57万
-
财政年份:2015
-
负责人:Kenneth Cusi
-
依托单位:
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
-
批准号:10447175
-
项目类别:
-
资助金额:$45.57万
-
财政年份:2015
-
负责人:Kenneth Cusi
-
依托单位:
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
-
批准号:10684417
-
项目类别:
-
资助金额:$9.04万
-
财政年份:2015
-
负责人:Kenneth Cusi
-
依托单位:
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
-
批准号:10263499
-
项目类别:
-
资助金额:$9.04万
-
财政年份:2015
-
负责人:Kenneth Cusi
-
依托单位:
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
-
批准号:10252059
-
项目类别:
-
资助金额:$45.57万
-
财政年份:2015
-
负责人:Kenneth Cusi
-
依托单位:
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment
-
批准号:8601149
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Kenneth Cusi
-
依托单位:
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment
-
批准号:7783853
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Kenneth Cusi
-
依托单位:
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment
-
批准号:8196297
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Kenneth Cusi
-
依托单位:
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment
-
批准号:7689041
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Kenneth Cusi
-
依托单位:
海外基金